Systemic administration of the antisense oligonucleotide NS-089/NCNP-02 for skipping of exon 44 in patients with Duchenne muscular dystrophy: Study protocol for a phase I/II clinical trial. https://onlinelibrary.wiley.com/doi/abs/10.1002/npr2.12335 #Morpholino